HHS Reports identify Rampant Medicare Part D Fraud

6/24/2015 Two reports released on Tuesday highlight the persistence of Medicare fraud, especially involving the Part D prescription drug program. The reports follow the largest Healthcare Fraud takedown in history last week, as officials charged 46 doctors and pharmacy owners, as well as nearly 200 others for Medicare fraud. This includes the arrest of 44


House Will Vote to Repeal Key Obamacare Measures

6/18/2015 The House of Representatives will vote Thursday to repeal two controversial provisions to the Affordable Care Act (ACA), better known as Obamacare. Amidst a considerable degree of bipartisan support, Ways and Means Committee chairman, Paul Ryan (R-WI) successfully advanced measures to a vote earlier this month to cut the unpopular 2.3 percent tax on


FDA to consider new Class of Cholesterol Drugs

6/9/2015 A new class of cholesterol drugs will undergo a preliminary review this week from a Food and Drug Administration (FDA) advisory panel. The drugs, Amgen’s Evolocumab and Alirocumab from Sanofi SA and partner, Regeneron Pharmaceuticals, block a protein called PCSK9, which can prevent the liver from eliminating bad cholesterol. Early studies show the drugs



How long until Power Morcellators are Banned?

5/29/2015 Despite the ongoing FBI investigation of Johnson & Johnson’s manufacturing division, Ethicon, and a strong Food and Drug Administration (FDA) warning issued last year, power morcellators are still legal. The device grinds up tissue mass, and is then removed through a series of small incisions. The device, which is used to provide minimally invasive


SGLT2 Clinical Research and Side-Effects

5/19/2015 The Food and Drug Administration’s (FDA) May 15th warning of potential ketoacidosis among Type II diabetes patients who use a new class of oral treatments known as SGLT2 inhibitors should not be completely surprising. The first such medicine approved by the FDA in March, 2013 was Invokana (canagliflozin), manufactured by Janssen Pharmaceuticals in conjunction



Medtronic’s Preemption Win in the 10th Circuit – With An Interesting Twist

The Tenth Circuit issued an opinion on Tuesday, finding that state law claims asserted against Medtronic, manufacturer of the InFuse bone growth stimulator were preempted by FDA approval of the medical device under the Medical Device Act (“MDA”). Plaintiff in the case alleged that Medtronic representatives promoted an off-label, posterior surgical approach for the device,



JPML Maintains Narrow Focus of Mirena MDL

The orders from the March JPML panel hearing have been posted, and the JPML issued an order denying a motion by a plaintiff to centralize her case in the Mirena IUD device litigation MDL proceeding in the SDNY.  In its order, the JPML indicated that centralization into the pending MDL was denied because the potential